Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
InMed Pharmaceuticals Inc. INM
$1.17
-$0.03 (-2.50%)
На 18:03, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
3927276.00000000
-
week52high
23.68
-
week52low
0.92
-
Revenue
1089435
-
P/E TTM
0
-
Beta
1.05813100
-
EPS
-22.97000000
-
Last Dividend
0.00000000
-
Next Earnings Date
11 мая 2023 г. в 12:30
Описание компании
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies; and IntegraSyn, an integrated biosynthesis-based manufacturing approach, for synthesizing pharmaceutical-grade cannabinoids. It has a research collaboration agreement with BayMedica Inc. for the manufacturing and testing of novel cannabinoid therapeutics. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | 22 дек 2021 г. | |
| Roth Capital | Buy | Buy | 16 февр 2021 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Lemerond Nicole | A | 1400 | 840 | 16 дек 2022 г. |
| Tegge Jonathan | A | 1400 | 1400 | 16 дек 2022 г. |
| Li Sarah | A | 4002 | 3600 | 16 дек 2022 г. |
| WOUDENBERG MICHAEL | A | 11342 | 7500 | 16 дек 2022 г. |
| Johnson Shane Aaron | A | 8000 | 4200 | 16 дек 2022 г. |
| Grove Janet P | A | 1400 | 840 | 16 дек 2022 г. |
| HULL ANDREW | A | 1484 | 840 | 16 дек 2022 г. |
| Baldasare Bryan T | A | 1400 | 840 | 16 дек 2022 г. |
| ADAMS ERIC A | A | 28502 | 15000 | 16 дек 2022 г. |
| HSU ERIC C | A | 8878 | 4200 | 16 дек 2022 г. |
Новостная лента
InMed (INM) Gets Grant to Begin Neurodegenerative Diseases Program
Zacks Investment Research
17 ноя 2022 г. в 12:02
InMed Pharmaceuticals (INM) surges on receiving research grant funding from the Natural Sciences and Engineering Research Council of Canada (NSERC) to investigate its cannabinoid drug candidates.
InMed stock rockets after research grant awarded for cannabinoid analogs to treat Alzheimer's, Parkinson's
Market Watch
16 ноя 2022 г. в 12:13
Shares of InMed Pharmaceuticals Inc. INM, +52.16% rocketed 50.9% on very heavy volume in midday trading Wednesday, after the company said it was awarded a grant from the Natural Sciences and Engineering Research Council of Canada (NSERC) to support research and development of its cannabinoid drug candidates for the potential treatment of neurodegenerative diseases, such as Alzheimer's, Parkinson's and Huntington's. Trading volume spiked to 19.5 million shares, compared with the full-day average of about 148,200 shares.
InMed Pharmaceuticals Inc. (INM) Q4 2022 Earnings Call Transcript
Seeking Alpha
23 сент 2022 г. в 15:28
InMed Pharmaceuticals Inc. (NASDAQ:INM ) Q4 2022 Results Conference Call September 23, 2022 1:00 PM ET Company Participants Colin Clancy - VP, IR Eric Adams - President and CEO Michael Woudenberg - COO Brenda Edwards - Interim CFO Dr. Eric Hsu - SVP, Preclinical Research and Development Conference Call Participants Scott Henry - ROTH Capital Partners Raghuram Selvaraju - H.C. Wainwright Operator Good day.
InMed Pharmaceuticals to Report Full Year Fiscal 2022 Financial Results and Business Update on September 23, 2022
GlobeNewsWire
19 сент 2022 г. в 18:00
VANCOUVER, British Columbia, Sept. 19, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development and manufacturing of rare cannabinoids, will report financial results on Friday, September 23, 2022 for the fiscal year ended June 30, 2022.
Why Is InMed (INM) Stock Up 60% Today?
InvestorPlace
12 сент 2022 г. в 13:59
The relief rally we've seen play out last week is once again in full focus on Monday. All major indices have moved higher today.